Xenetic Biosciences Inc
0.8301 - 0.92
0.4538 - 3.42
Join Discuss about XBIO with like-minded investors
Next Dividend Date
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
HQ: 40 Speen St Ste 102 Framingham, 01701-1898 Massachusetts